402 related articles for article (PubMed ID: 29184673)
1. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.
Manicone M; Poggiana C; Facchinetti A; Zamarchi R
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1346-S1358. PubMed ID: 29184673
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of liquid biopsy for the diagnosis and monitoring of
Sánchez-Herrero E; Provencio M; Romero A
Adv Lab Med; 2020 Mar; 1(1):20190019. PubMed ID: 37362555
[TBL] [Abstract][Full Text] [Related]
3. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.
Tomasik B; Skrzypski M; Bieńkowski M; Dziadziuszko R; Jassem J
Transl Lung Cancer Res; 2023 Mar; 12(3):594-614. PubMed ID: 37057121
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
Transl Res; 2024 Jun; 272():41-53. PubMed ID: 38838851
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.
Manicone M; Scaini MC; Rodriquenz MG; Facchinetti A; Tartarone A; Aieta M; Zamarchi R; Rossi E
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1391-S1396. PubMed ID: 29184678
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.
Zografos E; Dimitrakopoulos FI; Koutras A
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230877
[TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
[TBL] [Abstract][Full Text] [Related]
9. Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?
Pailler E; Faugeroux V; Oulhen M; Catelain C; Farace F
Transl Lung Cancer Res; 2017 Aug; 6(4):444-453. PubMed ID: 28904888
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
11. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.
Pesta M; Shetti D; Kulda V; Knizkova T; Houfkova K; Bagheri MS; Svaton M; Polivka J
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892510
[TBL] [Abstract][Full Text] [Related]
12. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
14. What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC).
Pezzuto A; Manicone M; Scaini MC; Ricci A; Mariotta S; Zamarchi R; Rossi E
J Thorac Dis; 2018 Jul; 10(7):E570-E576. PubMed ID: 30174936
[TBL] [Abstract][Full Text] [Related]
15. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
Morrison GJ; Goldkorn A
Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets.
Kulasinghe A; Kapeleris J; Cooper C; Warkiani ME; O'Byrne K; Punyadeera C
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30889898
[TBL] [Abstract][Full Text] [Related]
17. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
18. Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.
Kapeleris J; Ebrahimi Warkiani M; Kulasinghe A; Vela I; Kenny L; Ladwa R; O'Byrne K; Punyadeera C
Front Oncol; 2022; 12():859152. PubMed ID: 35372000
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Diao Z; Han Y; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.
Pérez-Callejo D; Romero A; Provencio M; Torrente M
Transl Lung Cancer Res; 2016 Oct; 5(5):455-465. PubMed ID: 27826527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
